Trial intelligence / Profile preview

ZOSTAVAX concomitant versus nonconcomitant administration with inactivated influenza vaccine in adults aged 50 years or older

2005-003035-52Phase 3Completed

Sponsor: Merck & Co.
Start: Aug 2005
Modality: Live Biotherapeutic Products → Microbiome Therapeutics, Vaccines & Immunotherapeutics
Countries: 1

Overview

Phase 3, randomised, double-blind trial of zoster vaccine, live in herpes zoster (HZ) and influenza (2 arms), sponsored by Merck & Co. Primary endpoints: Varicella-zoster virus antibody geometric mean titer at 4 weeks, Influenza strain-specific antibody geometric mean titers at 4 weeks and 1 more. Started Aug 2005; status: completed.

Drugs

zoster vaccine, live

Conditions

herpes zoster (HZ)influenza

Beyond the preview

Go deeper on 2005-003035-52.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on 2005-003035-52.